![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, April 17, 2024 1:09:09 PM
They plan on CONTINUING TO DUMP SHARES on the open market and DILUTING their shareholders with no end in sight.
"Our goal is to ensure that we can continue our development of stenoparib, strongly encouraged by the significant early data we have received so far from our ongoing monotherapy trial in advanced ovarian cancer."
In other words stenoparib is still not ready for phase 3. They are going to have to chemically modify it to try to improve it which means repeating phase 1 and phase 2 trials. They are going to need a A LOT more time and money and there is no guarantee at all that they can get it modified to the point it needs to be at.
This is a TOXIC investment. If there happens to be a pump, sell for what you can and get out. They are just going to continue with the reverse splits followed by dilution for the foreseeable future as they have no revenue, no product, and thomas jackass jensen needs to collect his handsome salary.
![Bearish](/static/images/ih2-bear.png)
Recent ALLR News
- Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:54:31 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/24/2024 12:55:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 12:15:26 PM
- Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement • GlobeNewswire Inc. • 05/20/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/17/2024 08:08:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:15:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:45:38 PM
- Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances • GlobeNewswire Inc. • 05/14/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/09/2024 03:21:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 01:47:15 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/08/2024 08:05:18 PM
- Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock • GlobeNewswire Inc. • 05/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:29:16 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 01:13:42 PM
- Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) • GlobeNewswire Inc. • 04/17/2024 01:10:00 PM
- Allarity Therapeutics Announces 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 04/04/2024 01:15:00 PM
- Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:38:56 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 12:15:55 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM